Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of lopinavir to medicines

A new use and medical technology, applied in the field of chemical medicine, can solve the problems of unreported pharmacological effects

Inactive Publication Date: 2016-07-27
BINZHOU MEDICAL COLLEGE
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Clinically, the combination of lopinavir and ritonavir (trade name Kaletra) is used for the treatment of HIV / AIDS infection, and it can also be used in combination with other antiretroviral drugs for the treatment of HIV infection in adults and children over 6 months old , but the pharmacological effects of lopinavir in the prevention or treatment of obesity, type II diabetes, diabetic nephropathy and non-alcoholic fatty liver have not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of lopinavir to medicines
  • New application of lopinavir to medicines
  • New application of lopinavir to medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] Example 1 Preparation of Lopinavir Capsules

[0014] Weigh 50.0g of lopinavir and 150.0g of carboxymethyl starch sodium, mix well and pass through a 100-mesh sieve, add an appropriate amount of 3% PVP K30 Appropriate amount of water solution to prepare soft material, granulate with 20-mesh sieve, dry at 60°C for 3 hours, sieve with 18-mesh sieve for granulation, add 2.0g of magnesium stearate, mix well and pack into capsules, adjust the weight of the capsules to about 200mg.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a new application of lopinavir to medicines and in particular relates to an application of lopinavir to medicines for preventing or treating obesity, type II diabetes, diabetic nephropathy and non-alcoholic fatty liver diseases. The oral dosage of lopinavir ranges between 50mg and 2000mg in application, preferably 50-1000mg.

Description

technical field [0001] The invention belongs to the field of chemical medicine, and relates to a new medical application of lopinavir; in particular, it relates to preventing or treating obesity, type II diabetes, Diabetic nephropathy and non-alcoholic fatty liver and other related metabolic disorders. Background technique [0002] Type 2 diabetes is adult-onset diabetes, accounting for more than 90% of diabetic patients. People with type 2 diabetes are obese and develop insulin resistance, resulting in decreased sensitivity to insulin. Diabetic nephropathy is an important complication of diabetes, and nearly 40% of patients with late diabetes will develop diabetic nephropathy. Obesity is an unhealthy state of body fat accumulation and weight gain due to calorie intake exceeding consumption. The incidence of obesity is increasing rapidly in both developed countries and developing countries, and it is showing a trend of younger age. It has become a global epidemic that ser...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/513A61P3/04A61P3/10A61P13/12A61P1/16
CPCA61K31/513
Inventor 蒋王林张广华纪云霞朱海波
Owner BINZHOU MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com